Publications by authors named "Barry Mirtsching"

Claim this Profile
I
Irinotecan-induced immune thrombocytopenia.
Barry C Mirtsching, James N George, Richard H Aster, Brian R Curtis

Am J Med Sci· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
Barry Mirtsching, Thomas Cosgriff, Graydon Harker, Mark Keaton, Tarek Chidiac

Clin Breast Cancer· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.
Lee Schwartzberg, Ronald Burkes, Barry Mirtsching, Timothy Rearden, Peter Silberstein

BMC Cancer· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
Philip A Philip, Jacqueline Benedetti, Christopher L Corless, Ralph Wong, Eileen M O'Reilly, Barry C Mirtsching

J Clin Oncol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
Howard Ozer, Barry Mirtsching, Michael Rader, Susan Luedke, Stephen J Noga

Oncologist· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Heinz-Josef Lenz, Eric Van Cutsem, Shirin Khambata-Ford, Robert J Mayer, Philip Gold, Barry Mirtsching

J Clin Oncol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.
Saroj Vadhan-Raj, Barry Mirtsching, Veena Charu, Dixon Terry, Gregory Rossi

J Support Oncol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature.
Susan S Lee, Michael R Robinson, John C Morris, Barry C Mirtsching, DeFen Shen

Surv Ophthalmol· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
Barry Mirtsching, Veena Charu, Saroj Vadhan-Raj, Alan B Colowick, Gregory Rossi

Oncology (Williston Park)· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis